RadioMedix

Focus: RadioMedix is a radiopharmaceutical and imaging technology company headquartered in Houston, TX, focused on oncology and nephrology applications. The company operates as a public entity with a specialized pipeline in nuclear medicine and related manufacturing.

Oncology Nephrology Nuclear Medicine Manufacturing

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About RadioMedix

AI assessmentNot Hiring

No open roles listed right now. Follow RadioMedix to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

AminoMedixTM for Kidney Protection During Radionuclide Therapy

Radiation Nephropathy

N/A

Clinical Trials (1)

NCT05785663AminoMedixTM for Kidney Protection During Radionuclide Therapy

N/A

Help build intelligence for RadioMedix

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in high-growth radiopharmaceutical space with 5 active programs spanning Phase 2-3, including 64Cu-DOTATATE in Phase 3 for neuroendocrine tumors
Specialized expertise in niche oncology and nephrology indications with limited direct competition, offering differentiation in a consolidating market
Public company status provides stability and exit clarity, with radiopharmaceutical expertise increasingly valuable as nuclear medicine gains FDA and payer traction

Watch Out For

Minimal hiring activity with only 2 active roles (both in Quality Assurance), suggesting limited growth or organizational stagnation
No published financial data, clinical trial publications, or recent news available, raising transparency concerns about company trajectory and scientific productivity

Generated by Claude from RadioMedix's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

68Ga-DOTATATE

Neuroendocrine Carcinoma

N/A

Clinical Trials (1)

NCT0187965768Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

N/A

68Ga-PSMA

Prostate Cancer

PHASE_2

Clinical Trials (1)

NCT0228213768Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer

Phase 2